Back to top

Analyst Blog

The U.S. Food and Drug Administration (FDA) accepted the New Drug Application (NDA) for Spectrum Pharmaceuticals’ (SPPI - Snapshot Report) Beleodaq. Spectrum Pharma is looking to get Beleodaq approved in the U.S. for the treatment of patients suffering from relapsed or refractory peripheral T-cell lymphoma (R/R PTCL).

Spectrum Pharma also mentioned that the FDA will review its application for Beleodaq on a priority basis. A final decision from the U.S. regulatory body on the approval of the candidate is expected by Aug 9, 2014.

The NDA submission was based on positive results from a study on Beleodaq for the above indication. Results revealed an acceptable safety profile and clinical efficacy of the candidate. An overall response rate of 26% was also observed in the heavily pre-treated patient population including patients who had received allogeneic or autologous stem cell transplant.

We are encouraged by Spectrum Pharma’s progress with Beleodaq. Spectrum Pharma gained development and commercialization rights to Beleodaq (North America, India and with an option for China) following a licensing and collaboration agreement with TopoTarget A/S in 2010.

Apart from Beleodaq, Spectrum Pharma also has captisol-enabled melphalan in its pipeline. The candidate is being developed as a conditioning agent for stem cell transplant and multiple myeloma. The company expects to report top-line data from a pivotal study on captisol-enabled melphalan in the second quarter of 2014. Spectrum Pharma intends to file an NDA for the candidate soon after.

Spectrum Pharma currently carries a Zacks Rank #2 (Buy). Some other stocks worth considering include Actelion Ltd. (ALIOF), Biogen Idec Inc. (BIIB - Analyst Report) and WuXi PharmaTech (Cayman) Inc. (WX - Snapshot Report). While Actelion and Biogen carry a Zacks Rank #1 (Strong Buy), WuXi Pharma carries a Zacks Rank #2.

Please login to Zacks.com or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research

Close

Are you a new Zacks Member or a visitor to Zacks.com?

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
PLANAR SYST… PLNR 4.44 +5.21%
BITAUTO HOL… BITA 81.71 +5.12%
CTPARTNERS… CTP 16.66 +4.26%
CHINA BIOLO… CBPO 47.91 +3.30%
MALLINCKROD… MNK 72.94 +2.85%